Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.6%

3 terminated/withdrawn out of 22 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

78%

7 of 9 completed trials have results

Key Signals

2 recruiting7 with results

Enrollment Performance

Analytics

Phase 2
11(50.0%)
Phase 1
10(45.5%)
Early Phase 1
1(4.5%)
22Total
Phase 2(11)
Phase 1(10)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT03236428Phase 2Active Not Recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Role: collaborator

NCT03091257Phase 1Active Not Recruiting

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

NCT02718833Phase 2Active Not Recruiting

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Role: collaborator

NCT01562405Phase 1Active Not Recruiting

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT05560399Early Phase 1Active Not Recruiting

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT02253316Phase 2Active Not Recruiting

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Role: collaborator

NCT06171685Phase 2Recruiting

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

Role: lead

NCT07053436Phase 2Not Yet Recruiting

Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma

Role: lead

NCT02765854Phase 2Completed

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Role: collaborator

NCT03732703Phase 1Completed

Myeloma-Developing Regimens Using Genomics (MyDRUG)

Role: lead

NCT04150965Phase 1Terminated

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Role: lead

NCT03773107Phase 1Completed

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Role: collaborator

NCT06107738Phase 2Recruiting

Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Role: collaborator

NCT01183949Phase 1Completed

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Role: collaborator

NCT02903381Phase 2Completed

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Role: collaborator

NCT02279394Phase 2Completed

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Role: collaborator

NCT03252600Phase 2Unknown

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Role: collaborator

NCT02952573Phase 2Terminated

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Role: collaborator

NCT01497093Phase 1Completed

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT01549431Phase 1Completed

Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

Role: collaborator